Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

The U.S. Food and Drug Administration and the pharmaceutical company Novo Nordisk are urging consumers to be on the lookout ...

Novo Nordisk (NYSE: NVO) has seen revenue soar in recent years thanks to two drugs that have helped people around the world ...

Novo Nordisk filed for approval of an oral, 25-mg formulation of semaglutide “earlier this year,” according to a company spokesperson.

With a history dating back more than 100 years, Novo Nordisk has long been a leader in diabetes care. Its breakthrough came with the development of semaglutide, a GLP-1 receptor agonist.

As STAT points out, Novo Nordisk doesn't have any comparable small-molecule drug to Eli Lilly's orforglipron. Its own injectable peptide, semaglutide, which is the active ingredient in both ...

With as much as $17 billion in sales in 2024, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). This Scandinavian economic behemoth ...

Novo Nordisk (NYSE:NVO) stock has experienced a significant decline, dropping 35% from over $90 in early March to around $58 currently. Several factors have contributed to this downward trend.